NCT01020799 - AZD7268 Safety and Tolerability Study | Biotech Hunter

Enrollment

247

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Major Depressive Disorder

Interventions

DRUG

AZD7268

15 mg, oral, twice daily (BID)

DRUG

Escitalopram

20 mg, oral, once daily (QD)

DRUG

Placebo capsules

Placebo capsules to match AZD7268

DRUG

Placebo tablets

Placebo tablets to match encapsulated escitalopram

Trial Locations (17)

Research Site, Birmingham

Research Site, Garden Grove

Research Site, San Diego

Research Site, New Haven

Research Site, Bradenton

Research Site, Jacksonville

Research Site, Atlanta

Research Site, Rockville

Research Site, Cedarhurst

Research Site, New York

Research Site, Rochester

Research Site, Dayton

Research Site, Portland

Research Site, Memphis

Research Site, Friendswood

Research Site, Bellevue

Research Site, Seattle